Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.

Onco Targets Ther · 2011 · PMC3143911 · PMID 21792318

Europe PMC DOI

hedged sentence

0.3740

closest p · 7.5× alpha

0.3740

boldest claim

The sentences

did not reach statistical significanceP = 0.374not close (p > 0.1)

The OS in the nab-paclitaxel group was greater than that in CrEL-paclitaxel group (65.0 weeks vs 55.7 weeks, respectively), but this did not reach statistical significance ( P = 0.374).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.